Navigation Links
Biopure Announces 2008 Third Quarter Financial Results
Date:8/21/2008

also corresponded with regulatory authorities disparaging Hemopure. Notwithstanding the absence in clinical use of the adverse effects for HBOCs noted by the authors, citing the article, one South African state recommended against using Hemopure and an insurer suspended coverage of the product. The Company is in discussions with health agencies in South Africa and other countries to respond to their concerns.

Cost of revenues was $2.4 million for the third fiscal quarter of 2008, compared to $3.1 million for the same period in 2007. Cost of revenues includes costs of both Oxyglobin and Hemopure. Hemopure cost of revenues, consisting primarily of the allocation of unabsorbed fixed manufacturing costs, was $1.6 million for the third fiscal quarter of 2008 compared to $2.5 million for the same period in 2007. During the third fiscal quarter of 2008 the Company took measures to reduce its cash burn, including a 58 % workforce reduction, cutting facilities maintenance costs and curtailment of manufacturing. Oxyglobin cost of revenues was $747,000 for the third fiscal quarter of 2008 compared to $636,000 for the same period in 2007 due mostly to the increase in unit sales mentioned above, partially offset by the cost reductions.

Expenses

Research and development expenses were $914,000 for the third fiscal quarter of 2008 compared to $1.6 million for the same period in 2007. During the third fiscal quarter of 2008 spending on clinical and preclinical trials decreased by $313,000, consulting and outside services decreased by $178,000 and salaries decreased by $111,000 compared to the same period in 2007.

Sales and marketing expenses decreased to $232,000 for the third quarter of fiscal 2008, from $341,000 for the same period in 2007. During fiscal 2007 the Company spent $84,000 in market research for the U.K.

General and administrative expenses were $1.8 million for the third fiscal quarter of 2008 compared to $2.1 million for the same per
'/>"/>

SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Biopure Announces Private Equity Financing
2. Biopure Granted Additional 180 Day Compliance Period by NASDAQ
3. Biopure Announces MHRA Meeting Update
4. Biopure Announces 2008 Second Quarter Financial Results
5. Biopure Appoints Dechra Exclusive U.S. Distributor of Oxyglobin
6. Biopure Announces Date to Meet with UKs Medicines and Healthcare Products Agency
7. Biopure Operations Compliant With U.K. Manufacturing Guidelines
8. Biopure Appoints New Independent Auditor
9. Biopure Completes U.K. Regulatory Agency Inspection
10. Biopure Announces 2008 First Quarter Financial Results
11. Biopure Launches Updated Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- Research and Markets  has announced the ... Polymer, Food & Beverage, Personal Care & Pharmaceutical) ... report to their offering. Lactic acid ... carbon atom. The main applications of lactic acid ... personal care product, and pharmaceutical industries. Lactic ...
(Date:8/27/2014)... 2014  A novel biomarker for rheumatoid arthritis ... identify early-stage disease, when treatment can often arrest ... new study in The Journal of Rheumatology. ... DGX ) and other institutions found that elevated ... antibody-serum testing, including rheumatoid factor (RF) and anti-citrullinated ...
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 ... of Guggenheim Partners, today announced the hiring of veteran ... and senior equity analyst. Mr. Butler will focus on ... brings our team a wealth of experience and a ... Dante Ferrarie , Senior Managing Director and Head of ...
(Date:8/27/2014)... August 27, 2014 Flagship Biosciences LLC, ... services to the pharmaceutical and medical device industries, has ... The fast growing company has consolidated its histology and ... Boulder to Westminster, CO, just north of Denver. ... 7575 W. 103rd Ave., Suite 100, Westminster, CO 80021 ...
Breaking Biology Technology:Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Flagship Biosciences Announces Relocation and Expansion 2
... NEW YORK and MONTREAL, Dec. 21 /PRNewswire-FirstCall/ - ICBS Ltd. ... state and municipal regulatory bodies for the sale of the ... Solutions will be moving to target regulatory agencies in the ... advantages not only on time advantage (10 Hours for test ...
... III trials of OGX-011 in first- and second-line advanced ... begin in 2010 and early 2011 -- , -- ... to target resistance to cancer treatments -- , JERUSALEM, ... - Teva Pharmaceutical Industries Ltd. ( TEVA) and OncoGenex ...
... , , THOUSAND OAKS, Calif., Dec. ... Roger M. Perlmutter, M.D., Ph. D., Amgen,s executive vice ... Fellow of the American Association for the Advancement of Science ... on behalf of the advancement of science or its applications ...
Cached Biology Technology:BioSpec Global Solutions Inc. target market TOGS 9000 to state and municipal regulatory bodies in U.S. market 2Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 2Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 3Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 4Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 5Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 6Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 7Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 8Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines 2Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines 3
(Date:8/27/2014)... as giant, frightening beasts. But every creature is a ... slab containing fossils of 24 very young dinosaurs and ... hatchlings overseen by a caretaker, according to a new ... P. Hedrick and Peter Dodson led the work, collaborating ... where the specimen is held. Hedrick is a doctoral ...
(Date:8/27/2014)... that a deficiency in serotonin a chemical messenger ... depression. In the journal ACS Chemical Neuroscience , ... serotonin in their brains (and thus should have been ... , Donald Kuhn and colleagues at the John ... School of Medicine note that depression poses a major ...
(Date:8/27/2014)... have shown that excessive iron is closely ... Previous studies from Chunyan Guo and co-workers ... shown that baicalin prevented iron accumulation after ... 1 expression, and increased ferroportin 1 expression ... disease rats. However, the relationship between iron ...
Breaking Biology News(10 mins):Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3New study throws into question long-held belief about depression 2
... at the U.S. Department of Energy,s Lawrence Berkeley National ... into wispy nanoscale ropes that approach the structural complexity ... development in the push to develop self-assembling nanoscale materials ... but which are rugged enough to withstand harsh conditions ...
... Energy,s Pacific Northwest National Laboratory has been recognized for ... The award-winning partnerships are helping analyze trace amounts of ... and more easily study live cells., The Federal Laboratory ... 2011 for Excellence in Technology Transfer. The consortium is ...
... have proven that you don,t have to travel to exotic ... distinctive species of crayfish in Tennessee and Alabama that is ... genetic relative, once thought to be the only species in ... in Kentucky, can grow almost as big as a lobster. ...
Cached Biology News:A nanoscale rope, and another step toward complex nanomaterials that assemble themselves 2A nanoscale rope, and another step toward complex nanomaterials that assemble themselves 3PNNL recognized for technology transfer 2PNNL recognized for technology transfer 3Researchers discover giant crayfish species right under their noses 2Researchers discover giant crayfish species right under their noses 3Researchers discover giant crayfish species right under their noses 4
... ( Abpromise for all tested applications). ... conjugated to KLH derived from within residues ... 1.(Note: the amino acid sequence is proprietary)(Peptide ... Entrez GeneID: 1822 ...
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
BI-1 Polyclonal Antibody Storage Temperature: -20C Shipping: gel pack Shelf-Life: 12 months...
RAW; Collected from 8-12 week old sexually mature mice that are free of common parasites; RAW Collected from 8-12 week old sexually mature mice that are free of common parasites....
Biology Products: